<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140762</url>
  </required_header>
  <id_info>
    <org_study_id>V102_16</org_study_id>
    <nct_id>NCT02140762</nct_id>
  </id_info>
  <brief_title>Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents</brief_title>
  <official_title>A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness of 2 doses of MenABCWY vaccine in adolescents compared to a single
      dose of MenACWY vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the Second Vaccination.</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US N. Meningitidis Serogroup B Strain at 4 Months After the Second Vaccination.</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at One Month After the Second Vaccination</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at Four Months After the Second Vaccination.</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</measure>
    <time_frame>Baseline, one month after second vaccination (month 3)</time_frame>
    <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at one month after the 2-dose vaccination series is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</measure>
    <time_frame>Baseline, four months after second vaccination (month 6)</time_frame>
    <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at four months after the 2-dose vaccination series is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Enc-hSBA Titer &gt;= 1:4 and Enc-hSBA Titer &gt;= 1:8 at One Month After the 2-dose Vaccination Series</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA &gt;= 1:4 and enc-hSBA titer &gt;= 1:8 against four N. meningitidis serogroup B test strains at one month after the 2-dose vaccination series is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Enc-hSBA Titer ≥ 1:4 and Enc-hSBA Titer ≥ 1:8 at Four Months After the 2-dose Vaccination Series</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains at four months after the 2-dose vaccination series is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs against serogroup B test strains, at one month after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs against serogroup B test strains, at four months after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A,C,W,Y</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs to serogroups A, C, W, and Y, at one month after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A, C, W, Y</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs to serogroups A, C, W, and Y, at four months after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Baseline(Day 1) and One Month After the 2-dose Vaccination Series.</measure>
    <time_frame>At baseline(day 1) and One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at baseline(day 1) and one month after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ LLQ at Baseline and One Month After the 2-dose Vaccination Series</measure>
    <time_frame>At Baseline and One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ against serogroups A, C, W, Y, at baseline(day 1) and one month after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at four months after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ LLQ against serogroups A, C, W, Y at four months after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at four months after the 2-dose vaccination series, is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series</measure>
    <time_frame>Four months after the second vaccination (month 6)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 against serogroups A, C, W, Y at four months after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at one month after the 2-dose vaccination series, is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</measure>
    <time_frame>One month after the second vaccination (month 3)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128, against serogroups A, C, W, Y, at one month after the 2-dose vaccination series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 3-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A, C, W and Y at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 (one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a three-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y at 1 and 4 months after the 2-dose vaccination series.
The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</measure>
    <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
    <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>From day 1 (6 hours) until day 7 after any vaccination</time_frame>
    <description>Reactogenicity was presented in terms of number of subjects reporting solicited local and systemic AEs and other indicators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs.</measure>
    <time_frame>From day 1 to day 30 after any vaccination for any unsolicited AE. From day 1 to study termination (day 181) for all other categories.</time_frame>
    <description>Percentages of subjects reporting unsolicited AEs including serious adverse events (SAEs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>MenABCWY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/MenACWY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY</intervention_name>
    <description>Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
    <arm_group_label>MenABCWY</arm_group_label>
    <other_name>MenACWY conjugate combined with rMenB + OMV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL saline solution (IM)</description>
    <arm_group_label>Placebo/MenACWY</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY</intervention_name>
    <description>Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
    <arm_group_label>Placebo/MenACWY</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents from 10-18 years of age, generally in good health, and available for all
             study visits, who/whose legally acceptable representative has given written informed
             consent at the time of enrollment.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test.

        Exclusion Criteria:

          -  Serious, acute, or chronic illnesses. Previous or suspected disease caused by N.
             meningitidis. Previous immunization with any meningococcal vaccine.

          -  Exposure to individuals with clinically proven meningococcal disease or clinical
             bacterial meningitis without further microbiologic characterization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance, Inc</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro, P.A.</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance, Inc</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003 Jan 30;21(7-8):605-10.</citation>
    <PMID>12531326</PMID>
  </reference>
  <reference>
    <citation>Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011 Jul;11(7):969-85. doi: 10.1517/14712598.2011.585965. Epub 2011 May 26. Review.</citation>
    <PMID>21615224</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <results_first_submitted>February 11, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2018</results_first_posted>
  <disposition_first_submitted>April 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 6, 2015</disposition_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis ABCWY</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Meningococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 8 study sites in USA.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenABCWY</title>
          <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
        </group>
        <group group_id="P2">
          <title>Placebo/MenACWY</title>
          <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenABCWY</title>
          <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
        </group>
        <group group_id="B2">
          <title>Placebo/MenACWY</title>
          <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="2.18"/>
                    <measurement group_id="B2" value="12.2" spread="2.42"/>
                    <measurement group_id="B3" value="12" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>FEMALE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the Second Vaccination.</title>
        <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on Full Analysis Set (FAS) effectiveness (month 3): all subjects in the All Enrolled Set who received a study vaccination and provided evaluable serum sample with enc-hSBA for at least one N. meningitidis serogroup B invasive disease strain at one month after the 2-dose series (Visit Month 3).</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the Second Vaccination.</title>
          <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
          <population>Analysis was done on Full Analysis Set (FAS) effectiveness (month 3): all subjects in the All Enrolled Set who received a study vaccination and provided evaluable serum sample with enc-hSBA for at least one N. meningitidis serogroup B invasive disease strain at one month after the 2-dose series (Visit Month 3).</population>
          <units>Percentages of subjects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.17" spread="30.77"/>
                    <measurement group_id="O2" value="76.19" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0 (Null Hypothesis): Vaccine Effectiveness (VE) ≤10%. If the lower limit of the 95% CI for VE is &gt; 10% the null hypothesis is to be rejected and effectiveness declared. The VE at 1 month after the 2nd injection for each strain is defined as [1-(% of subjects without bactericidal activity at 1:4 dilution in MenABCWY group / % of subjects without bactericidal activity at 1:4 dilution in MenACWY group)]x100. The combined VE across all strains will be computed by mean of a generalized linear model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Generalized Linear Model</method>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65</ci_lower_limit>
            <ci_upper_limit>69</ci_upper_limit>
            <estimate_desc>VE is based on the relative risk (RR). The Poisson Distribution and Log Link options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval. Fixed effects: treatment group, strain (and center).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>vaccine effectiveness&lt;10% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity strains in ABCWY)/(% of not killed strains/without bactericidal activity strains in ACWY)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>4.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness &lt;30% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity strains in ABCWY)/(% of not killed strains/without bactericidal activity strains in ACWY)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>12.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;60% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity strains in ABCWY)/(% of not killed strains/without bactericidal activity strains in ACWY)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>18.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness &lt;100% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity strains in ABCWY)/(% of not killed strains/without bactericidal activity strains in ACWY)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>59.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US N. Meningitidis Serogroup B Strain at 4 Months After the Second Vaccination.</title>
        <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on FAS effectiveness (month 6): All subjects in the All Enrolled Set who received a study vaccination and provided evaluable serum sample with enc-hSBA for at least one N. meningitidis serogroup B invasive disease strain at four months after the 2-dose series (Visit Month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US N. Meningitidis Serogroup B Strain at 4 Months After the Second Vaccination.</title>
          <description>The combined percentage of subjects without bactericidal activity at 1:4 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:4 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
          <population>Analysis was done on FAS effectiveness (month 6): All subjects in the All Enrolled Set who received a study vaccination and provided evaluable serum sample with enc-hSBA for at least one N. meningitidis serogroup B invasive disease strain at four months after the 2-dose series (Visit Month 6).</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.91" spread="33.429"/>
                    <measurement group_id="O2" value="76.67" spread="27.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0 (Null Hypothesis): Vaccine Effectiveness (VE) ≤10%. If the LL of the 95% CI for VE is &gt; 10% the null hypothesis is to be rejected and effectiveness declared. The VE at 4 months after the second injection for each strain is defined as [1 - (% of subjects without bactericidal activity at 1:4 dilution in MenABCWY group / % of subjects without bactericidal activity at 1:4 dilution in MenACWY group)] x 100.The combined VE across all strains will be computed by mean of a generalized linear model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>General Linear Model (GLM)</method>
            <param_type>Vaccine effectiveness</param_type>
            <param_value>44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41</ci_lower_limit>
            <ci_upper_limit>47</ci_upper_limit>
            <estimate_desc>VE is based on the relative risk (RR). The POISSON DISTRIBUTION and LOG LINK options was used in the generalized linear model to compute the log10 RR and the corresponding confidence interval. Fixed effects: treatment group, strain (and center).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;10% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:4 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>9.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;30% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:4 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>22.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;60% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:4 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>19.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;100% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:4 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>38.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at One Month After the Second Vaccination</title>
        <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on FAS effectiveness ( month 3)</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at One Month After the Second Vaccination</title>
          <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at one month after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
          <population>Analysis was done on FAS effectiveness ( month 3)</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="37.04"/>
                    <measurement group_id="O2" value="88.28" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0 (Null Hypothesis): Vaccine Effectiveness (VE) ≤ 10%. If the lower limit of the 95% CI for VE is &gt;10% the null hypothesis is to be rejected and effectiveness declared. The VE at 1 month after the 2nd injection for each strain is defined as [1-(% of subjects without bactericidal activity at 1:8 dilution in MenABCWY group / % of subjects without bactericidal activity at 1:8 dilution in MenACWY group)]x100. The combined VE across all strains will be computed by mean of a generalized linear model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Generalized Linear Model</method>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43</ci_lower_limit>
            <ci_upper_limit>49</ci_upper_limit>
            <estimate_desc>VE is based on the relative risk (RR).The Poisson Distribution and Log Link options were used in the generalized linear model to compute the log10 RR and the corresponding confidence interval. Fixed effects:treatment group, strain (and center).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;10% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>25.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;30%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>19.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;60% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>10.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;100% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>40.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at Four Months After the Second Vaccination.</title>
        <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on FAS effectiveness (month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at Four Months After the Second Vaccination.</title>
          <description>The combined percentage of subjects without bactericidal activity at 1:8 dilution using the endogenous complement human Serum Bactericidal Assay (enc-hSBA) across all strains in MenABCWY group and MenACWY group is reported at four months after the second injection. The percentage of subjects without bactericidal activity at 1:8 dilution was used to assess the effectiveness of two doses of MenABCWY vaccine when compared to one dose of Men ACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains.
Least Square (LS)-mean computed from the generalized linear model.</description>
          <population>Analysis was done on FAS effectiveness (month 6).</population>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.89" spread="29.625"/>
                    <measurement group_id="O2" value="88.53" spread="21.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0 (Null Hypothesis): Vaccine Effectiveness (VE) ≤10%. If the lower limit of 95% CI for VE is &gt; 10% the null hypothesis is to be rejected and effectiveness declared. The VE at 4 months after the 2nd injection for each strain is defined as [1 - (% of subjects without bactericidal activity at 1:8 dilution in MenABCWY group/% of subjects without bactericidal activity at 1:8 dilution in MenACWY group)] x 100. The combined VE across all strains was computed by mean of a generalized linear model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>VE is based on the relative risk (RR). The POISSON DISTRIBUTION and LOG LINK options was used in the generalized linear model to compute the log10 RR and the corresponding confidence interval. Fixed effects: treatment group, strain (and center).</p_value_desc>
            <method>Generalized Linear Model</method>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16</ci_lower_limit>
            <ci_upper_limit>23</ci_upper_limit>
            <estimate_desc>VE is based on the relative risk (RR). The POISSON DISTRIBUTION and LOG LINK options was used in the generalized linear model to compute the log10 RR and the corresponding confidence interval. Fixed effects: treatment group, strain (and center).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;10% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>36.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;30% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>15.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;60% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>20.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine effectiveness&lt;100% For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated. For each strain, vaccine effectiveness (VE) of the MenABCWY compared to MenACWY was evaluated as VE= [1- (% not killed/without bactericidal activity at 1:8 dilution in MenABCWY group)/(% of not killed strains/without bactericidal activity in ACWY group)*100].</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine effectiveness at one month after the second vaccination against each of the endemic US N.meningitidis serogroup B strains. Each individual strain data was analysed separately with treatment group as only independent variable in the model.</non_inferiority_desc>
            <param_type>Vaccine Effectiveness</param_type>
            <param_value>11.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</title>
        <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at one month after the 2-dose vaccination series is reported.</description>
        <time_frame>Baseline, one month after second vaccination (month 3)</time_frame>
        <population>Analysis was done on FAS effectiveness (month 3)</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</title>
          <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at one month after the 2-dose vaccination series is reported.</description>
          <population>Analysis was done on FAS effectiveness (month 3)</population>
          <units>Mean percentages of strains</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (1:4) (N=136, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.08" spread="16.25"/>
                    <measurement group_id="O2" value="19.76" spread="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 2nd vaccination (1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.47" spread="14.55"/>
                    <measurement group_id="O2" value="22.93" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (1:8) (N=136, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" spread="8.35"/>
                    <measurement group_id="O2" value="9.54" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 2nd vaccination (1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.16" spread="17.11"/>
                    <measurement group_id="O2" value="11.39" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</title>
        <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at four months after the 2-dose vaccination series is reported.</description>
        <time_frame>Baseline, four months after second vaccination (month 6)</time_frame>
        <population>Analysis was done on FAS effectiveness (month 6).</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of N. Meningitidis Serogroup B Invasive Disease Strains Killed at 1:4 and 1:8 Dilutions, for Each Subject</title>
          <description>The mean percentage of N. meningitidis serogroup B invasive disease strains killed by each subject, at 1:4 and 1:8 dilutions at four months after the 2-dose vaccination series is reported.</description>
          <population>Analysis was done on FAS effectiveness (month 6).</population>
          <units>Mean percentage of strains</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (1:4) (N=133, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.82" spread="16.227"/>
                    <measurement group_id="O2" value="19.73" spread="15.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months after 2nd vaccination (1:4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.38" spread="18.703"/>
                    <measurement group_id="O2" value="22.66" spread="16.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (1:8) (N=133, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.19" spread="8.336"/>
                    <measurement group_id="O2" value="9.52" spread="9.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months after 2nd vaccination (1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.52" spread="18.484"/>
                    <measurement group_id="O2" value="11.19" spread="11.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Enc-hSBA Titer &gt;= 1:4 and Enc-hSBA Titer &gt;= 1:8 at One Month After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA &gt;= 1:4 and enc-hSBA titer &gt;= 1:8 against four N. meningitidis serogroup B test strains at one month after the 2-dose vaccination series is reported.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on FAS Immunogenicity (Month 3): all subjects in the All Enrolled Set who received a study vaccination, provided evaluable serum samples respectively at 1 month post-second vaccination (Visit Month 3) whose immunogenicity assay result is available for at least one N. meningitidis serogroup B test strain or serogroups A, C, W or Y.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Enc-hSBA Titer &gt;= 1:4 and Enc-hSBA Titer &gt;= 1:8 at One Month After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA &gt;= 1:4 and enc-hSBA titer &gt;= 1:8 against four N. meningitidis serogroup B test strains at one month after the 2-dose vaccination series is reported.</description>
          <population>Analysis was done on FAS Immunogenicity (Month 3): all subjects in the All Enrolled Set who received a study vaccination, provided evaluable serum samples respectively at 1 month post-second vaccination (Visit Month 3) whose immunogenicity assay result is available for at least one N. meningitidis serogroup B test strain or serogroups A, C, W or Y.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254 (1:4, 1 month after 2nd vacc) (N=132,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="57.9" upper_limit="74.6"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (1:8, 1 month after 2nd vacc) (N=132,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="17.2" upper_limit="32.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (1:4, 1 month after 2nd vacc) (N=134,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.5" upper_limit="98.3"/>
                    <measurement group_id="O2" value="12" lower_limit="7.3" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (1:8, 1 month after 2nd vacc) (N=134,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="55.4" upper_limit="72.3"/>
                    <measurement group_id="O2" value="3" lower_limit="0.9" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084(1:4,1 month after 2nd vacc)(N=131,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="49.8" upper_limit="67.3"/>
                    <measurement group_id="O2" value="20" lower_limit="13.3" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084(1:8,1 month after 2nd vacc)(N=131,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="14.7" upper_limit="29.4"/>
                    <measurement group_id="O2" value="7" lower_limit="2.9" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (1:4, 1 month after 2nd vacc) (N=93,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.1" upper_limit="100"/>
                    <measurement group_id="O2" value="49" lower_limit="37.6" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (1:8, 1 month after 2nd vacc) (N=93,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.2" upper_limit="99.97"/>
                    <measurement group_id="O2" value="15" lower_limit="7.8" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Enc-hSBA Titer ≥ 1:4 and Enc-hSBA Titer ≥ 1:8 at Four Months After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains at four months after the 2-dose vaccination series is reported.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Enc-hSBA Titer ≥ 1:4 and Enc-hSBA Titer ≥ 1:8 at Four Months After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY vaccine, in terms of percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains at four months after the 2-dose vaccination series is reported.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254(1:4) (N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8.9" upper_limit="21.6"/>
                    <measurement group_id="O2" value="5" lower_limit="1.7" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254(1:8) (N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.8" upper_limit="7.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.19" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (1:4) (N=103,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="73.8" upper_limit="89.3"/>
                    <measurement group_id="O2" value="20" lower_limit="13.4" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459(1:8) (N=103,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="18" upper_limit="35.8"/>
                    <measurement group_id="O2" value="3" lower_limit="0.5" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (1:4) (N=121,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="24.8" upper_limit="42.2"/>
                    <measurement group_id="O2" value="19" lower_limit="12.6" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084(1:8) (N=121,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3.5" upper_limit="13.7"/>
                    <measurement group_id="O2" value="7" lower_limit="2.9" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (1:4) (N=87,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O2" value="64" lower_limit="52.7" upper_limit="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (1:8) (N=87,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87.1" upper_limit="98.1"/>
                    <measurement group_id="O2" value="14" lower_limit="7.5" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</title>
        <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs against serogroup B test strains, at one month after the 2-dose vaccination series.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on FAS Immunogenicity (Month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</title>
          <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs against serogroup B test strains, at one month after the 2-dose vaccination series.</description>
          <population>Analysis was done on FAS Immunogenicity (Month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254 (1 month after 2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" lower_limit="5.16" upper_limit="7.03"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.89" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (1 month after 2nd vacc) (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="11" upper_limit="16"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.92" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (1 month after 2nd vacc) (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.08" upper_limit="6.26"/>
                    <measurement group_id="O2" value="1.65" lower_limit="1.33" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (1 month after 2nd vacc) (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.22" lower_limit="133" upper_limit="215"/>
                    <measurement group_id="O2" value="3.16" lower_limit="2.48" upper_limit="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</title>
        <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs against serogroup B test strains, at four months after the 2-dose vaccination series.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroup B Test Strains</title>
          <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs against serogroup B test strains, at four months after the 2-dose vaccination series.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.53" upper_limit="2"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.93" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.6" upper_limit="3.56"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.96" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" lower_limit="1.47" upper_limit="2.12"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.3" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.85" lower_limit="45" upper_limit="74"/>
                    <measurement group_id="O2" value="3" lower_limit="2.35" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A,C,W,Y</title>
        <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs to serogroups A, C, W, and Y, at one month after the 2-dose vaccination series.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on FAS Immunogenicity (Month 3)</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A,C,W,Y</title>
          <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of hSBA GMTs to serogroups A, C, W, and Y, at one month after the 2-dose vaccination series.</description>
          <population>Analysis was done on FAS Immunogenicity (Month 3)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (1 month after 2nd vacc) (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.02" lower_limit="59" upper_limit="101"/>
                    <measurement group_id="O2" value="22.08" lower_limit="17" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (1 month after 2nd vacc) (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.88" lower_limit="171" upper_limit="325"/>
                    <measurement group_id="O2" value="38.61" lower_limit="28" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (1 month after 2nd vacc) (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.72" lower_limit="120" upper_limit="207"/>
                    <measurement group_id="O2" value="37.51" lower_limit="28" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (1 month after 2nd vacc) (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.43" lower_limit="110" upper_limit="220"/>
                    <measurement group_id="O2" value="27.76" lower_limit="19" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A, C, W, Y</title>
        <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs to serogroups A, C, W, and Y, at four months after the 2-dose vaccination series.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>HT-hSBA Geometric Mean Titers (GMTs) Against the N. Meningitidis Serogroups A, C, W, Y</title>
          <description>The immunogenicity of two doses of MenABCWY compared to a single dose of MenACWY vaccine, in terms of HT-hSBA GMTs to serogroups A, C, W, and Y, at four months after the 2-dose vaccination series.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.91" lower_limit="9.19" upper_limit="18"/>
                    <measurement group_id="O2" value="5.56" lower_limit="3.99" upper_limit="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.18" lower_limit="84" upper_limit="163"/>
                    <measurement group_id="O2" value="25.64" lower_limit="19" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.22" lower_limit="70" upper_limit="119"/>
                    <measurement group_id="O2" value="42.97" lower_limit="33" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.51" lower_limit="42" upper_limit="85"/>
                    <measurement group_id="O2" value="19.53" lower_limit="14" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Baseline(Day 1) and One Month After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at baseline(day 1) and one month after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively.</description>
        <time_frame>At baseline(day 1) and One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Baseline(Day 1) and One Month After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at baseline(day 1) and one month after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>96217 -Baseline (N=108,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="21.2" upper_limit="39.2"/>
                    <measurement group_id="O2" value="32" lower_limit="23.6" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217- Month 3 (N=119,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.4" upper_limit="99.98"/>
                    <measurement group_id="O2" value="30" lower_limit="21.6" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Baseline (N=123,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.9" upper_limit="8.1"/>
                    <measurement group_id="O2" value="7" lower_limit="3.3" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Month 3 (N=117,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="25.7" upper_limit="43.5"/>
                    <measurement group_id="O2" value="10" lower_limit="5.4" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-baseline(N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.02" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-month 3 (N=131,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="64.9" upper_limit="80.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.49" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Baseline(N=131,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.02" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Month 3(N=131,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="34.9" upper_limit="52.5"/>
                    <measurement group_id="O2" value="2" lower_limit="0.19" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ LLQ at Baseline and One Month After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ against serogroups A, C, W, Y, at baseline(day 1) and one month after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
        <time_frame>At Baseline and One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ LLQ at Baseline and One Month After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ against serogroups A, C, W, Y, at baseline(day 1) and one month after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A -baseline(N=128,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.19" upper_limit="5.5"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A- Month 3(N=130,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87.3" upper_limit="96.8"/>
                    <measurement group_id="O2" value="63" lower_limit="52.9" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-baseline(N=130,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="23.7" upper_limit="40.3"/>
                    <measurement group_id="O2" value="43" lower_limit="34.2" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-Month 3(N=127,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="82" lower_limit="73.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-baseline(N=116,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6.8" upper_limit="19.4"/>
                    <measurement group_id="O2" value="16" lower_limit="9.9" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 3 (N=112,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="83.1" upper_limit="95.0"/>
                    <measurement group_id="O2" value="52" lower_limit="42.6" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-baseline(N=122,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5.2" upper_limit="16.6"/>
                    <measurement group_id="O2" value="11" lower_limit="5.8" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 3(N=102,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.3" upper_limit="98.9"/>
                    <measurement group_id="O2" value="70" lower_limit="59.8" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at four months after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ LLQ, at four months after the 2-dose vaccination series, is reported. The LLQ cut off values for strains 96217, M07-0241084,M14459 and NZ98/254 were 8.6, 8.9, 8 and 8.2 respectively</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>96217 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.3" upper_limit="98.3"/>
                    <measurement group_id="O2" value="30" lower_limit="22.4" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459(N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19.1" upper_limit="34.7"/>
                    <measurement group_id="O2" value="1" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0231084 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5.6" upper_limit="17.0"/>
                    <measurement group_id="O2" value="10" lower_limit="5.6" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254(N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.8" upper_limit="15.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ LLQ against serogroups A, C, W, Y at four months after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ Lower Limit of Quantitation (LLQ) at Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ LLQ against serogroups A, C, W, Y at four months after the 2-dose vaccination series.The LLQ cut off values for serogroups A,C,W and Y were 22.7,5.2,39.6 and 14.7 respectively.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (N=124, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39.3" upper_limit="57.5"/>
                    <measurement group_id="O2" value="32" lower_limit="24.4" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.7" upper_limit="99.82"/>
                    <measurement group_id="O2" value="78" lower_limit="70.2" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="69.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="58" lower_limit="48.7" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="77.6" upper_limit="90.5"/>
                    <measurement group_id="O2" value="63" lower_limit="54.0" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at four months after the 2-dose vaccination series, is reported.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at four months after the 2-dose vaccination series, is reported.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254 ≥ 5 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8.8" upper_limit="21.4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.46" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 8 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.7" upper_limit="15.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 16 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.8" upper_limit="7.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 32 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.18" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 64 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.18" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 128 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.02" upper_limit="4.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 5 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="30.8" upper_limit="47.9"/>
                    <measurement group_id="O2" value="3" lower_limit="0.8" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 8 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19.1" upper_limit="34.7"/>
                    <measurement group_id="O2" value="1" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 16 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.7" upper_limit="15.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 32 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.47" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 64 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.02" upper_limit="4.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 128 (N=133,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 5 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="23.4"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 8 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.2" upper_limit="17.9"/>
                    <measurement group_id="O2" value="11" lower_limit="6.2" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 16 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2.3" upper_limit="11.1"/>
                    <measurement group_id="O2" value="8" lower_limit="3.8" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 32 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.49" upper_limit="6.8"/>
                    <measurement group_id="O2" value="2" lower_limit="0.19" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 64 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.02" upper_limit="4.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥128 (N=126,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 5 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.3" upper_limit="98.3"/>
                    <measurement group_id="O2" value="35" lower_limit="27.3" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 8 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.3" upper_limit="98.3"/>
                    <measurement group_id="O2" value="32" lower_limit="23.8" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 16 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87.4" upper_limit="96.8"/>
                    <measurement group_id="O2" value="22" lower_limit="15.1" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 32 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="68.9" upper_limit="84"/>
                    <measurement group_id="O2" value="8" lower_limit="3.7" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 64 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39.3" upper_limit="57"/>
                    <measurement group_id="O2" value="5" lower_limit="1.7" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 128 (N=131,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12.7" upper_limit="26.9"/>
                    <measurement group_id="O2" value="2" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 against serogroups A, C, W, Y at four months after the 2-dose vaccination series.</description>
        <time_frame>Four months after the second vaccination (month 6)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose after visit month 2</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at Four Months After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 against serogroups A, C, W, Y at four months after the 2-dose vaccination series.</description>
          <population>Analysis was done on the FAS immunogenicity (month 6). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A ≥ 8 (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="63" upper_limit="79.5"/>
                    <measurement group_id="O2" value="43" lower_limit="34.4" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 16 (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="56.3" upper_limit="73.6"/>
                    <measurement group_id="O2" value="38" lower_limit="29.3" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 32 (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="27.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="29" lower_limit="21.6" upper_limit="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 64 (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10.1" upper_limit="23.8"/>
                    <measurement group_id="O2" value="17" lower_limit="10.9" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 128 (N=124,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1.8" upper_limit="10.2"/>
                    <measurement group_id="O2" value="8" lower_limit="4.3" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 8 (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92.5" upper_limit="99.2"/>
                    <measurement group_id="O2" value="75" lower_limit="67" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 16 (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87.5" upper_limit="96.9"/>
                    <measurement group_id="O2" value="55" lower_limit="46" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 32 (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74.4" upper_limit="88.1"/>
                    <measurement group_id="O2" value="44" lower_limit="35" upper_limit="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 64 (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="58.2" upper_limit="74.8"/>
                    <measurement group_id="O2" value="32" lower_limit="23.8" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 128 (N=133,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="37.9" upper_limit="55.5"/>
                    <measurement group_id="O2" value="26" lower_limit="18.4" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 8 (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="87" lower_limit="79.9" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 16 (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.3" upper_limit="98.3"/>
                    <measurement group_id="O2" value="82" lower_limit="74.6" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 32 (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="76.5" upper_limit="89.8"/>
                    <measurement group_id="O2" value="66" lower_limit="57.3" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 64 (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="52.2" upper_limit="69.5"/>
                    <measurement group_id="O2" value="39" lower_limit="30.8" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 128 (N=131,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="27.7" upper_limit="44.7"/>
                    <measurement group_id="O2" value="24" lower_limit="16.8" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 8 (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="82.8" upper_limit="94.1"/>
                    <measurement group_id="O2" value="67" lower_limit="58.7" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 16 (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="75.9" upper_limit="89.3"/>
                    <measurement group_id="O2" value="61" lower_limit="52.5" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 32 (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="63.5" upper_limit="79.4"/>
                    <measurement group_id="O2" value="48" lower_limit="39.7" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 64 (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="41.2" upper_limit="58.8"/>
                    <measurement group_id="O2" value="37" lower_limit="28.9" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 128 (N=132,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="24" upper_limit="40.5"/>
                    <measurement group_id="O2" value="19" lower_limit="12.6" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at one month after the 2-dose vaccination series, is reported.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against Serogroup B Test Strains≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers against serogroup B test strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at one month after the 2-dose vaccination series, is reported.</description>
          <population>Analysis was done on the FAS immunogenicity (month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NZ98/254 ≥ 5 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="51.5" upper_limit="68.4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 8 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="36.5" upper_limit="53.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.18" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 16 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11.5" upper_limit="24.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 32 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2.1" upper_limit="10.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 64 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.45" upper_limit="6.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 ≥ 128 (N=138,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.18" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 5 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="75.2" upper_limit="88.5"/>
                    <measurement group_id="O2" value="4" lower_limit="1.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 8 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="65" upper_limit="80.4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.47" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 16 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="47.1" upper_limit="64.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 32 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.8" upper_limit="30.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit=".28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 64 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3.5" upper_limit="12.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 ≥ 128 (N=138,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 5 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="40.9" upper_limit="59.1"/>
                    <measurement group_id="O2" value="16" lower_limit="9.6" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 8 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="31.6" upper_limit="49.5"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 16 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="13.5" upper_limit="28.3"/>
                    <measurement group_id="O2" value="7" lower_limit="2.9" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 32 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1.8" upper_limit="10.2"/>
                    <measurement group_id="O2" value="2" lower_limit="0.5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥ 64 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 ≥128 (N=124,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 5 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.6" upper_limit="99.98"/>
                    <measurement group_id="O2" value="34" lower_limit="25.4" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 8 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.6" upper_limit="99.98"/>
                    <measurement group_id="O2" value="31" lower_limit="23.1" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 16 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.3" upper_limit="99.8"/>
                    <measurement group_id="O2" value="21" lower_limit="14.2" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 32 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.8" upper_limit="98.7"/>
                    <measurement group_id="O2" value="13" lower_limit="7.3" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 64 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="80.8" upper_limit="93.1"/>
                    <measurement group_id="O2" value="4" lower_limit="1.4" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217 ≥ 128 (N=124,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="57.1" upper_limit="74.4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.21" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128, against serogroups A, C, W, Y, at one month after the 2-dose vaccination series.</description>
        <time_frame>One month after the second vaccination (month 3)</time_frame>
        <population>Analysis was done on the FAS immunogenicity (month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at One Month After the 2-dose Vaccination Series</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with HT-hSBA titers ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128, against serogroups A, C, W, Y, at one month after the 2-dose vaccination series.</description>
          <population>Analysis was done on the FAS immunogenicity (month 3). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A ≥ 8 (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.7" upper_limit="99.55"/>
                    <measurement group_id="O2" value="72" lower_limit="63" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 16 (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.7" upper_limit="98.4"/>
                    <measurement group_id="O2" value="69" lower_limit="59.4" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 32 (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="83.4" upper_limit="94.3"/>
                    <measurement group_id="O2" value="57" lower_limit="47.8" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 64 (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="57.1" upper_limit="73.6"/>
                    <measurement group_id="O2" value="42" lower_limit="32.6" upper_limit="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A ≥ 128 (N=137,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23.7" upper_limit="39.9"/>
                    <measurement group_id="O2" value="19" lower_limit="12.4" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 8 (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.9" upper_limit="99.98"/>
                    <measurement group_id="O2" value="74" lower_limit="65.8" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 16 (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.9" upper_limit="99.98"/>
                    <measurement group_id="O2" value="64" lower_limit="54.9" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 32 (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.6" upper_limit="99.54"/>
                    <measurement group_id="O2" value="52" lower_limit="42.9" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 64 (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77" upper_limit="90"/>
                    <measurement group_id="O2" value="39" lower_limit="30.6" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C ≥ 128 (N=134,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="59.3" upper_limit="75.7"/>
                    <measurement group_id="O2" value="30" lower_limit="22.5" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 8 (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.4" upper_limit="99.98"/>
                    <measurement group_id="O2" value="86" lower_limit="78.4" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 16 (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.1" upper_limit="99.8"/>
                    <measurement group_id="O2" value="81" lower_limit="72.5" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 32 (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85.1" upper_limit="95.9"/>
                    <measurement group_id="O2" value="61" lower_limit="51.3" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 64 (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="70.6" upper_limit="85.9"/>
                    <measurement group_id="O2" value="36" lower_limit="26.9" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W ≥ 128 (N=119,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="48.6" upper_limit="67"/>
                    <measurement group_id="O2" value="23" lower_limit="16.1" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 8 (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.7" upper_limit="99"/>
                    <measurement group_id="O2" value="71" lower_limit="61" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 16 (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.4" upper_limit="98.5"/>
                    <measurement group_id="O2" value="69" lower_limit="58.8" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 32 (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84.6" upper_limit="96.1"/>
                    <measurement group_id="O2" value="63" lower_limit="52.2" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 64 (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="70.5" upper_limit="86.6"/>
                    <measurement group_id="O2" value="48" lower_limit="37.5" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y ≥ 128 (N=107,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="49.9" upper_limit="69.2"/>
                    <measurement group_id="O2" value="30" lower_limit="20.8" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA</description>
        <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
        <population>Analysis was performed on FAS immunogenicity- month 3 and month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA</description>
          <population>Analysis was performed on FAS immunogenicity- month 3 and month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>96217-Month 3(N=101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85.0" upper_limit="96.5"/>
                    <measurement group_id="O2" value="6" lower_limit="2.3" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Month 3(N=115,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.5" upper_limit="20.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.20" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-Month 3(N=137,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="46.8" upper_limit="64.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Month 3(N=136,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11.0" upper_limit="24.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217-Month 6(N=106,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="72.4" upper_limit="88.1"/>
                    <measurement group_id="O2" value="5" lower_limit="2.0" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Month 6(N=117,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.5" upper_limit="7.3"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-Month 6(N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.8" upper_limit="15.3"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Month 6(N=131,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.47" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 3-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
        <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
        <population>Analysis was performed on FAS immunogenicity-month 3 and month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 3-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
          <population>Analysis was performed on FAS immunogenicity-month 3 and month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>96217-month 3(N=101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="83.8" upper_limit="95.8"/>
                    <measurement group_id="O2" value="2" lower_limit="0.25" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0231084-month 3(N=115,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3.6" upper_limit="14.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-month 3(N=137,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="26.4" upper_limit="42.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-month 3(N=136,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5.2" upper_limit="15.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217-Month 6(N=106,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="60.1" upper_limit="78.4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.22" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Month 6(N=117,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.21" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-Month 6(N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1.2" upper_limit="8.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Month 6(N=131,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.47" upper_limit="6.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
        <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
        <population>Analaysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroup B Strains at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroup B test strains, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
          <population>Analaysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>96217-month 3(N=101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79.0" upper_limit="93.0"/>
                    <measurement group_id="O2" value="1" lower_limit="0.03" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0231084-month 3(N=115,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.21" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-month 3(N=137,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.3" upper_limit="29.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/25-month 3(N=136,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2.1" upper_limit="10.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96217-Month 6(N=106,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="53.3" upper_limit="72.4"/>
                    <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084-Month 6(N=117,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.21" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459-Month 6(N=132,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.47" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-Month 6(N=131,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.19" upper_limit="5.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA.</description>
        <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
        <population>Analysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 2-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a two-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 2-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥2 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 2 times of the prevaccination hSBA.</description>
          <population>Analysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A-month 3(N=132,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="73.3" upper_limit="87.4"/>
                    <measurement group_id="O2" value="48" lower_limit="38.6" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-month 3(N=131,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.6" upper_limit="99.81"/>
                    <measurement group_id="O2" value="66" lower_limit="56.8" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-month 3(N=107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="64.5" upper_limit="81.9"/>
                    <measurement group_id="O2" value="25" lower_limit="17.2" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 3(N=99,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84.7" upper_limit="96.5"/>
                    <measurement group_id="O2" value="59" lower_limit="48.2" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A-Month 6(N=119,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="15.5" upper_limit="31.3"/>
                    <measurement group_id="O2" value="21" lower_limit="13.9" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-Month 6(N=130,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.2" upper_limit="97.3"/>
                    <measurement group_id="O2" value="55" lower_limit="45.7" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 6(N=114,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="43.9" upper_limit="62.9"/>
                    <measurement group_id="O2" value="30" lower_limit="22.0" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 6(N=122,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="63.3" upper_limit="79.9"/>
                    <measurement group_id="O2" value="47" lower_limit="38.0" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A, C, W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a three-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y at 1 and 4 months after the 2-dose vaccination series.
The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
        <time_frame>At Month 3 and Month 6 (one and four months after 2 doses of vaccination)</time_frame>
        <population>Analysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 3-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A, C, W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a three-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y at 1 and 4 months after the 2-dose vaccination series.
The 3-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥3 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 3 times of the prevaccination hSBA.</description>
          <population>Analysis was performed on FAS immunogenicity-Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A-Month 6(N=119,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.9" upper_limit="20.9"/>
                    <measurement group_id="O2" value="14" lower_limit="8.7" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-Month 6(N=130,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81.7" upper_limit="93.4"/>
                    <measurement group_id="O2" value="48" lower_limit="38.9" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 6(N=114,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="24.0" upper_limit="41.9"/>
                    <measurement group_id="O2" value="22" lower_limit="14.5" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 6(N=122,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51.4" upper_limit="69.4"/>
                    <measurement group_id="O2" value="40" lower_limit="31.7" upper_limit="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A-Month 3(N=132,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51.7" upper_limit="69.0"/>
                    <measurement group_id="O2" value="36" lower_limit="27.4" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-Month 3(N=131,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.6" upper_limit="99.81"/>
                    <measurement group_id="O2" value="58" lower_limit="48.5" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 3(N=107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="46.2" upper_limit="65.7"/>
                    <measurement group_id="O2" value="19" lower_limit="12.3" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 3(N=99,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="76.2" upper_limit="91.3"/>
                    <measurement group_id="O2" value="50" lower_limit="39.0" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
        <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
        <time_frame>At Month 3 and Month 6 ( one and four months after 2 doses of vaccination)</time_frame>
        <population>Analysis was performed on FAS immunogenicity- Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
MenABCWY: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
Placebo: 0.5 mL saline solution (IM)
MenACWY: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 4-fold Rise in hSBA Titer Against N.Meningitidis Serogroups A,C,W and Y at One and Four Months After the 2-dose Vaccination Series.</title>
          <description>The immunogenicity of two doses of MenABCWY vaccine compared to a single dose of MenACWY, in terms of the percentages of subjects with a 4-fold rise in HT-hSBA titers against the N.meningitidis serogroups A,C,W and Y, at 1 and 4 months after the 2-dose vaccination series.
The 4-fold rise in titer is defined as follows:
a)for subjects with prevaccination hSBA titers &lt;LLQ, a postvaccination hSBA ≥4 LLQ; b) for subjects with a prevaccination hSBA titers ≥LLQ, an increase of at least 4 times of the prevaccination hSBA.</description>
          <population>Analysis was performed on FAS immunogenicity- Month 3 and Month 6. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A-Month 3(N=132,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="36.0" upper_limit="53.6"/>
                    <measurement group_id="O2" value="26" lower_limit="18.4" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-month 3(N=131,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.3" upper_limit="97.8"/>
                    <measurement group_id="O2" value="54" lower_limit="44.4" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 3(N=107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39.7" upper_limit="59.4"/>
                    <measurement group_id="O2" value="15" lower_limit="8.4" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-month 3(N=99,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="71.7" upper_limit="88.0"/>
                    <measurement group_id="O2" value="47" lower_limit="35.7" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A-Month 6(N=119,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3.5" upper_limit="13.9"/>
                    <measurement group_id="O2" value="11" lower_limit="6.2" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C-Month 6(N=130,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79.0" upper_limit="91.6"/>
                    <measurement group_id="O2" value="43" lower_limit="34.4" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-Month 6(N=114,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="19.3" upper_limit="36.3"/>
                    <measurement group_id="O2" value="17" lower_limit="10.9" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y-Month 6(N=122,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="40.0" upper_limit="58.4"/>
                    <measurement group_id="O2" value="35" lower_limit="26.3" upper_limit="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Reactogenicity was presented in terms of number of subjects reporting solicited local and systemic AEs and other indicators.</description>
        <time_frame>From day 1 (6 hours) until day 7 after any vaccination</time_frame>
        <population>Analysis was done on Solicited Safety Set: all subjects in the All Exposed Set who have provided any solicited adverse event data and/or other indicators or reactogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Reactogenicity was presented in terms of number of subjects reporting solicited local and systemic AEs and other indicators.</description>
          <population>Analysis was done on Solicited Safety Set: all subjects in the All Exposed Set who have provided any solicited adverse event data and/or other indicators or reactogenicity</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (mm) (N=149,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm) (N=149,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=149,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=148,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of pain/fever (N=149,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of pain/fever (N=149,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs.</title>
        <description>Percentages of subjects reporting unsolicited AEs including serious adverse events (SAEs).</description>
        <time_frame>From day 1 to day 30 after any vaccination for any unsolicited AE. From day 1 to study termination (day 181) for all other categories.</time_frame>
        <population>Analysis was done on the unsolicited safety set, ie, all subjects in the exposed set with any unsolicited adverse event data and/or indicators of unsolicited adverse events. Analysis for AEs leading to withdrawal was done on All Enrolled Set population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenABCWY</title>
            <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/MenACWY</title>
            <description>Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs.</title>
          <description>Percentages of subjects reporting unsolicited AEs including serious adverse events (SAEs).</description>
          <population>Analysis was done on the unsolicited safety set, ie, all subjects in the exposed set with any unsolicited adverse event data and/or indicators of unsolicited adverse events. Analysis for AEs leading to withdrawal was done on All Enrolled Set population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or probably related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events (AEs): from Day 1 to Day 7 of each study vaccination. Unsolicited AEs from Day 1 to Day 30 after each vaccination. Serious AEs, medically attended AEs, AEs leading to withdrawal were collected for the whole duration of the study.</time_frame>
      <desc>Data are presented in terms of number of subjects reporting AEs and in terms of number of subjects reporting AEs with a frequency &gt;5% in at least one group. For serious AEs, analysis was done on Unsolicited Safety set. For solicited/unsolicited AEs with a frequency &gt;5%, analysis was done on Overall Safety Set.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenABCWY</title>
          <description>Subjects received one dose of MenABCWY vaccine at visit day 1 and a second dose at visit month 2.</description>
        </group>
        <group group_id="E2">
          <title>Placebo/MenACWY</title>
          <description>Subjects received one dose of placebo at visit day 1 and one dose of MenACWY vaccine at visit month 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

